Due to the site upgrade, your MY ACCOUNT logins will need to be updated. Please access Forgot Your Password to make this change. If you do not have an account, click here.

The B-Complex Vitamins B6, B12 and Folic Acid cut the number of people in half with accelerated brain shrinkage decreasing the risk of Alzheimer’s disease

Sep 13, 2010

Scientists from Oxford University said their two-year clinical trial was the largest to date into the effect of B vitamins on "mild cognitive impair-ment" - a major risk factor for Alzheimer's disease and other forms of dementia.

     Experts commenting on the findings said they were important and called for larger, longer full-scale clinical trials to see if the safety and effectiveness of B vitamins in the prevention of neurodegenerative conditions could be confirmed. "This is a very dramatic and striking result. It's much more than we could have predicted," states Dr. David Smith of Oxford's department of pharmacology, co-leader of the trial.

     "It is our hope that this simple and safe treatment will delay development of Alzheimer's in many people who suffer from mild memory problems."
Mild cognitive impairment (MCI) affects around 16 percent (the figure may be much higher due to under-reporting) of people aged over 70 worldwide and is characterized by slight problems with memory loss, language or other mental functions.

     MCI does not usually interfere with daily life, but around 50 percent of people diagnosed with it go on to develop the far more severe disease Alzheimer's disease within five years. Alzheimer's is a mind-wasting disease for which there are few treatments and no cure, and which affects 26 million people around the world.
     Dr. Smith and colleagues conducted a two-year trial with 168 volunteers with MCI who were given either a vitamin pill containing very high doses of folic acid, vitamin B6 and vitamin B12, or a placebo dummy pill. These B vitamins are known to control levels of an amino acid called homocysteine in the blood, and high blood levels of homocysteine are linked to an increased risk of developing Alzheimer's disease.

     Brain scans were taken at the beginning and the end of the trial to monitor the rate of brain shrinkage, or atrophy. The results, published in the Public Library of Science (PLoS) One journal, showed that on average the brains of those taking the vitamin treatment shrank at a rate of 0.76 percent a year, while those taking the dummy pill had an average brain shrinkage rate of 1.08 percent; about a 31% difference in rate. People who had the highest levels of homocysteine at the start of the trial benefited the most from the treatment, with their brains shrinking at half the rate of those on the placebo.

     Although the trial was not designed to measure cognitive ability, the researchers found those people who had lowest rates of shrinkage had the highest scores in mental tests. The study is published in the September 8th, 2010 issue of the journal PLoS One.